Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Microwave ablation boosts immunotherapy in advanced liver cancer study

NCT ID NCT06581497

Disease control Sponsor: The First People's Hospital of Neijiang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 52 adults with advanced liver cancer to see if adding microwave ablation (MWA) to immunotherapy works better than immunotherapy alone. MWA uses heat to destroy tumors and may help the immune system fight cancer more effectively. The researchers measured how long patients lived without the cancer getting worse and overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

52 people

The number who actually took part.

Started

Jan 2022

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The investigators applied inclusion criteria, requiring a score of 0-1 for the Eastern Cooperative Oncology Group Performance Status (ECOG PS), The study includes patients in BCLC phases B and C, classified as Child Pugh A or B (score ≤ 7 points), with an expected lifespan of at least 3 months. Other inclusion criteria are liver function ≤ twice the upper limit of the normal value, creatinine ≤ 1.5 times the upper limit of the normal value, serum albumin level \> 25 g/L, platelet count \> 50 × 10\^9/mm³, precursor activity \> 50%, total white blood cell count \> 1.5 × 10\^9/mm³, and hemoglobin level \> 80 g/m³. Primary exclusion criteria include interstitial lung disease, pulmonary fibrosis, autoimmune disease, and a history of liver transplantation.

Ages

19 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Gender is not limited, age range is 19-80 years old. * Meets the clinical diagnostic criteria for HCC. * Progress after first-line treatment. * CNLC staging: Stage IIa, IIb, or IIIb of advanced HCC. * Child Pugh liver function grading score 5-7 points. * The ECOG (Eastern Cooperative Oncology Group) score ranges from 0 to 1. * The patient has a certain degree of compliance with the treatment plan and follow-up performance. * For patients infected with hepatitis B, antiviral treatment with anti hepatitis B virus drugs should be carried out before receiving treatment; And the hepatitis B DNA titer of the patient was less than 10\^2 IU/ml. Exclusion Criteria: * It has been determined that the inclusion criteria cannot be met. * Enhanced CT or MRI shows more than 3 active lesions in the liver, and the shortest diameter of a single lesion is greater than 3cm. * There is a portal vein cancer thrombus present. * The extrahepatic metastatic lesions have not been well controlled. * Other treatments were received during the process of receiving immunotherapy or immunotherapy combined with MWA treatment. * There is active bleeding present. * There are interstitial lung diseases, pulmonary fibrosis, and autoimmune diseases present.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC Therapy adverse effect

Contacts and locations

Locations

  • The Second People's Hospital of Neijiang City

    Neijiang, Sichuan, 641000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.